A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
Public ClinicalTrials.gov record NCT04414618. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia
Study identification
- NCT ID
- NCT04414618
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Enrollment
- 42 participants
Conditions and interventions
Conditions
Interventions
- Opaganib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2020
- Primary completion
- Nov 25, 2020
- Completion
- Dec 22, 2020
- Last update posted
- Mar 20, 2022
2020
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute | Scottsdale | Arizona | 85258 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Ascension St. John Hospital | Detroit | Michigan | 48236 | — |
| Albany Medical Center | Albany | New York | 12208 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Memorial Herman Southeast Hospital | Houston | Texas | 77089 | — |
| Memorial Hermann, Memorial City Medical Center | Houston | Texas | 77204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04414618, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2022 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04414618 live on ClinicalTrials.gov.